Binding models of reversible inhibitors to type-B monoamine oxidase

被引:23
|
作者
Carrieri, A
Carotti, A
Barreca, ML
Altomare, C
机构
[1] Univ Bari, Dipartimento Farmacochim, I-70125 Bari, Italy
[2] Univ Messina, Dipartimento Farmacochim, I-98168 Messina, Italy
关键词
monoamine oxidase-B; reversible MAO-B inhibitors; three-dimensional quantitative structure-activity; relationships; docking calculations;
D O I
10.1023/A:1023815426730
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interest in the inhibitors of type-B monoamine oxidase has grown in recent years, due to the evidence for multiple roles of one such agent ( selegiline) in the pharmacological management of neurodegenerative disorders. A set of 130 reversible and selective inhibitors of MAO-B ( including tetrazole, oxadiazolone, and oxadiazinone derivatives) were taken from the literature and subjected to a three-dimensional quantitative structure - activity relationship (3D-QSAR) study, using CoMFA and GOLPE procedures. The steric and lipophilic fields, alone and in combination, provided us with informative models and satisfactory predictions (q(2) = 0.73). The validity of these models was checked against the 3D X-ray structure of human MAO-B. Flexible docking calculations, performed by using a new approach which took advantage from QXP and GRID computational tools, showed the diverse inhibitors to interact with MAO-B in a similar binding mode, irrespective of the heterocycle characterizing them. A significant trend of correlation was observed between estimated energies of the complexes and the experimental inhibition data.
引用
收藏
页码:769 / 778
页数:10
相关论文
共 50 条
  • [1] Binding models of reversible inhibitors to type-B monoamine oxidase
    Antonio Carrieri
    Andrea Carotti
    M. Letizia Barreca
    Cosimo Altomare
    Journal of Computer-Aided Molecular Design, 2002, 16 : 769 - 778
  • [2] SELECTIVE ACETYLENIC SUICIDE AND REVERSIBLE INHIBITORS OF MONOAMINE-OXIDASE TYPE-A AND TYPE-B
    KALIR, A
    SABBAGH, A
    YOUDIM, MBH
    BRITISH JOURNAL OF PHARMACOLOGY, 1981, 73 (01) : 55 - 64
  • [3] TYPE-B MONOAMINE-OXIDASE AND NEUROTOXINS
    NAOI, M
    MARUYAMA, W
    EUROPEAN NEUROLOGY, 1993, 33 : 31 - 37
  • [4] Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase
    M. Naoi
    W. Maruyama
    M. B. H. Youdim
    P. Yu
    A. A. Boulton
    InflammoPharmacology, 2003, 11 (2) : 175 - 181
  • [5] NEW MECHANISMS OF ACTION OF IRREVERSIBLE MONOAMINE-OXIDASE TYPE-B INHIBITORS
    LI, XM
    JUORIO, AV
    PATERSON, IA
    BOULTON, AA
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 1993, 18 (04): : 199 - 200
  • [6] MODES OF BINDING OF PHENYLETHYLAMINES (PEA) BY TYPE-A AND TYPE-B OF MONOAMINE-OXIDASE (MAO)
    ZELLER, EA
    HUPRIKAR, SV
    WILSON, WE
    FEDERATION PROCEEDINGS, 1977, 36 (03) : 721 - 721
  • [7] SIMPLE MICRODETERMINATION OF TYPE-B MONOAMINE-OXIDASE
    SUZUKI, O
    NOGUCHI, E
    YAGI, K
    BIOCHEMICAL PHARMACOLOGY, 1976, 25 (24) : 2759 - 2760
  • [8] Structural determinants for reversible inhibitors that specifically bind to human monoamine oxidase B but not to monoamine oxidase A
    Hubalek, F
    Binda, C
    Khalil, A
    Murugesan, T
    Li, M
    Mattevi, A
    Castagnoli, N
    Edmondson, D
    FASEB JOURNAL, 2004, 18 (08): : C191 - C191
  • [9] Type-B monoamine oxidase inhibitors in neurological diseases:clinical applications based on preclinical findings
    Marika Alborghetti
    Edoardo Bianchini
    Lanfranco De Carolis
    Silvia Galli
    Francesco E.Pontieri
    Domiziana Rinaldi
    NeuralRegenerationResearch, 2024, 19 (01) : 16 - 21
  • [10] Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings
    Alborghetti, Marika
    Bianchini, Edoardo
    De Carolis, Lanfranco
    Galli, Silvia
    Pontieri, Francesco E.
    Rinaldi, Domiziana
    NEURAL REGENERATION RESEARCH, 2024, 19 (01) : 16 - 21